| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 431 | 2024 | 3218 | 50.670 |
Why?
|
| Kidney Neoplasms | 420 | 2024 | 4312 | 43.340 |
Why?
|
| Anilides | 31 | 2024 | 409 | 7.940 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 118 | 2024 | 11712 | 6.990 |
Why?
|
| Antineoplastic Agents | 138 | 2024 | 13630 | 6.690 |
Why?
|
| Pyrroles | 52 | 2018 | 1137 | 6.340 |
Why?
|
| Vascular Endothelial Growth Factor A | 63 | 2023 | 3484 | 5.630 |
Why?
|
| Indoles | 52 | 2018 | 1829 | 5.580 |
Why?
|
| Nephrectomy | 48 | 2024 | 1016 | 5.450 |
Why?
|
| Angiogenesis Inhibitors | 45 | 2022 | 2049 | 4.880 |
Why?
|
| Pyridines | 46 | 2024 | 2879 | 4.800 |
Why?
|
| Molecular Targeted Therapy | 58 | 2024 | 2803 | 4.450 |
Why?
|
| Carcinoma, Transitional Cell | 34 | 2023 | 800 | 4.000 |
Why?
|
| Phenylurea Compounds | 35 | 2024 | 529 | 3.920 |
Why?
|
| Urologic Neoplasms | 27 | 2020 | 320 | 3.880 |
Why?
|
| Protein Kinase Inhibitors | 62 | 2023 | 5643 | 3.460 |
Why?
|
| Urinary Bladder Neoplasms | 44 | 2023 | 2276 | 3.420 |
Why?
|
| Prostatic Neoplasms | 110 | 2023 | 11345 | 3.220 |
Why?
|
| Neoplasm Metastasis | 84 | 2024 | 4902 | 3.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 17 | 2018 | 666 | 3.010 |
Why?
|
| Disease-Free Survival | 79 | 2024 | 6828 | 2.740 |
Why?
|
| Antibodies, Monoclonal | 39 | 2023 | 9185 | 2.560 |
Why?
|
| Niacinamide | 27 | 2017 | 414 | 2.560 |
Why?
|
| TOR Serine-Threonine Kinases | 32 | 2022 | 2058 | 2.490 |
Why?
|
| Humans | 753 | 2024 | 760621 | 2.370 |
Why?
|
| Proto-Oncogene Proteins c-met | 11 | 2020 | 567 | 2.290 |
Why?
|
| Neoplasms | 77 | 2024 | 22072 | 2.250 |
Why?
|
| Indazoles | 31 | 2024 | 302 | 2.250 |
Why?
|
| Androgen Antagonists | 33 | 2023 | 1442 | 2.230 |
Why?
|
| Aged | 345 | 2024 | 169152 | 2.220 |
Why?
|
| Middle Aged | 353 | 2024 | 220352 | 2.190 |
Why?
|
| Survival Analysis | 71 | 2024 | 10182 | 2.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 8 | 2024 | 1139 | 2.120 |
Why?
|
| Male | 450 | 2024 | 359744 | 2.090 |
Why?
|
| Cystectomy | 14 | 2018 | 697 | 2.050 |
Why?
|
| Immunotherapy | 39 | 2024 | 4642 | 1.950 |
Why?
|
| Quinolines | 8 | 2024 | 759 | 1.950 |
Why?
|
| Sirolimus | 17 | 2023 | 1547 | 1.910 |
Why?
|
| Sulfonamides | 25 | 2024 | 1977 | 1.850 |
Why?
|
| Urothelium | 13 | 2017 | 277 | 1.830 |
Why?
|
| Prognosis | 108 | 2024 | 29658 | 1.740 |
Why?
|
| Kaplan-Meier Estimate | 48 | 2024 | 6544 | 1.730 |
Why?
|
| Clinical Trials, Phase II as Topic | 27 | 2024 | 629 | 1.700 |
Why?
|
| Treatment Outcome | 155 | 2024 | 65017 | 1.700 |
Why?
|
| Female | 339 | 2024 | 391270 | 1.680 |
Why?
|
| Pyrimidines | 28 | 2024 | 3016 | 1.670 |
Why?
|
| Aged, 80 and over | 144 | 2024 | 58995 | 1.640 |
Why?
|
| Benzenesulfonates | 16 | 2012 | 165 | 1.610 |
Why?
|
| Bone Neoplasms | 10 | 2019 | 2532 | 1.550 |
Why?
|
| Prostate-Specific Antigen | 30 | 2023 | 2529 | 1.540 |
Why?
|
| Clinical Trials, Phase III as Topic | 25 | 2024 | 861 | 1.480 |
Why?
|
| Prostatectomy | 29 | 2019 | 1956 | 1.390 |
Why?
|
| Survival Rate | 59 | 2024 | 12808 | 1.380 |
Why?
|
| Vinblastine | 8 | 2019 | 487 | 1.380 |
Why?
|
| Antineoplastic Agents, Hormonal | 17 | 2023 | 1529 | 1.330 |
Why?
|
| Retrospective Studies | 141 | 2024 | 80372 | 1.240 |
Why?
|
| SEER Program | 40 | 2023 | 1530 | 1.220 |
Why?
|
| Chemotherapy, Adjuvant | 28 | 2024 | 3529 | 1.200 |
Why?
|
| Neoplasm Staging | 62 | 2024 | 11152 | 1.180 |
Why?
|
| Triazines | 2 | 2020 | 310 | 1.120 |
Why?
|
| Adult | 169 | 2024 | 219994 | 1.120 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 7 | 2024 | 307 | 1.110 |
Why?
|
| Cisplatin | 14 | 2020 | 1644 | 1.110 |
Why?
|
| Mutation | 46 | 2024 | 29932 | 1.090 |
Why?
|
| Carcinoma, Papillary | 6 | 2015 | 785 | 1.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 32 | 2024 | 8515 | 1.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2020 | 544 | 1.050 |
Why?
|
| Healthcare Disparities | 18 | 2023 | 3388 | 0.990 |
Why?
|
| Follow-Up Studies | 63 | 2024 | 39261 | 0.980 |
Why?
|
| Drug Resistance, Neoplasm | 15 | 2021 | 5253 | 0.980 |
Why?
|
| Carbonic Anhydrases | 3 | 2024 | 109 | 0.960 |
Why?
|
| Neoadjuvant Therapy | 19 | 2019 | 2821 | 0.950 |
Why?
|
| Neoplasm Recurrence, Local | 25 | 2023 | 9276 | 0.950 |
Why?
|
| Databases, Factual | 42 | 2024 | 8035 | 0.940 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 6 | 2021 | 1613 | 0.930 |
Why?
|
| Pyrazines | 3 | 2020 | 1199 | 0.930 |
Why?
|
| Medical Oncology | 14 | 2023 | 2313 | 0.930 |
Why?
|
| Germ-Line Mutation | 7 | 2022 | 1841 | 0.920 |
Why?
|
| Endogenous Retroviruses | 2 | 2022 | 111 | 0.910 |
Why?
|
| Indenes | 1 | 2024 | 58 | 0.900 |
Why?
|
| Randomized Controlled Trials as Topic | 39 | 2022 | 10344 | 0.880 |
Why?
|
| Protective Agents | 2 | 2014 | 150 | 0.870 |
Why?
|
| Imidazoles | 8 | 2017 | 1180 | 0.870 |
Why?
|
| Clinical Trials as Topic | 38 | 2021 | 8056 | 0.850 |
Why?
|
| Chromosomes, Human, X | 4 | 2024 | 321 | 0.840 |
Why?
|
| Salvage Therapy | 13 | 2019 | 1268 | 0.830 |
Why?
|
| Combined Modality Therapy | 26 | 2024 | 8552 | 0.820 |
Why?
|
| Urogenital Neoplasms | 2 | 2020 | 135 | 0.810 |
Why?
|
| Proportional Hazards Models | 41 | 2023 | 12531 | 0.800 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2014 | 629 | 0.770 |
Why?
|
| Translocation, Genetic | 5 | 2024 | 1388 | 0.750 |
Why?
|
| Immunoconjugates | 4 | 2023 | 949 | 0.750 |
Why?
|
| Taxoids | 7 | 2017 | 669 | 0.720 |
Why?
|
| Ubiquitin Thiolesterase | 6 | 2021 | 454 | 0.710 |
Why?
|
| Genomics | 19 | 2023 | 5794 | 0.710 |
Why?
|
| Therapies, Investigational | 1 | 2021 | 112 | 0.690 |
Why?
|
| Adrenocortical Carcinoma | 3 | 2016 | 88 | 0.680 |
Why?
|
| Neoplasms, Second Primary | 7 | 2018 | 1056 | 0.670 |
Why?
|
| Testicular Neoplasms | 7 | 2018 | 801 | 0.660 |
Why?
|
| Interleukin-8 | 2 | 2020 | 698 | 0.660 |
Why?
|
| Pandemics | 15 | 2023 | 8624 | 0.650 |
Why?
|
| Carcinoma | 9 | 2023 | 2331 | 0.650 |
Why?
|
| Lymphocytes | 5 | 2023 | 2611 | 0.640 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 210 | 0.630 |
Why?
|
| Early Detection of Cancer | 13 | 2023 | 3202 | 0.620 |
Why?
|
| Immunologic Factors | 6 | 2021 | 1588 | 0.620 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 3085 | 0.620 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 67 | 0.610 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 3205 | 0.610 |
Why?
|
| Brain Neoplasms | 11 | 2023 | 8986 | 0.610 |
Why?
|
| Radiosurgery | 3 | 2023 | 1343 | 0.600 |
Why?
|
| Melanoma | 11 | 2024 | 5697 | 0.590 |
Why?
|
| Radium | 1 | 2018 | 72 | 0.590 |
Why?
|
| Risk Factors | 73 | 2023 | 74359 | 0.580 |
Why?
|
| Indans | 1 | 2017 | 91 | 0.580 |
Why?
|
| Time Factors | 45 | 2024 | 40165 | 0.580 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 10 | 2021 | 1088 | 0.560 |
Why?
|
| Quality of Life | 19 | 2024 | 13308 | 0.550 |
Why?
|
| Drug Administration Schedule | 13 | 2019 | 4899 | 0.550 |
Why?
|
| Thromboembolism | 3 | 2012 | 1017 | 0.540 |
Why?
|
| Neoplasm Proteins | 9 | 2019 | 3610 | 0.530 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2016 | 161 | 0.530 |
Why?
|
| Deoxycytidine | 3 | 2017 | 873 | 0.530 |
Why?
|
| Lung Neoplasms | 16 | 2024 | 13262 | 0.530 |
Why?
|
| Gene Expression Profiling | 19 | 2021 | 9411 | 0.510 |
Why?
|
| Antigens, Neoplasm | 5 | 2024 | 1998 | 0.510 |
Why?
|
| Tumor Burden | 6 | 2022 | 1895 | 0.510 |
Why?
|
| Disease Progression | 26 | 2023 | 13502 | 0.510 |
Why?
|
| Young Adult | 37 | 2024 | 58741 | 0.510 |
Why?
|
| Hand Joints | 1 | 2016 | 58 | 0.510 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2021 | 2802 | 0.500 |
Why?
|
| Isoflavones | 2 | 2006 | 136 | 0.500 |
Why?
|
| Orchiectomy | 6 | 2016 | 470 | 0.500 |
Why?
|
| Sulfones | 1 | 2017 | 447 | 0.490 |
Why?
|
| Oligonucleotides | 1 | 2018 | 588 | 0.490 |
Why?
|
| Standard of Care | 2 | 2018 | 552 | 0.480 |
Why?
|
| Patient Selection | 10 | 2021 | 4283 | 0.480 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2021 | 10827 | 0.480 |
Why?
|
| Registries | 10 | 2023 | 8469 | 0.470 |
Why?
|
| United States | 71 | 2023 | 72461 | 0.470 |
Why?
|
| Angiotensins | 1 | 2015 | 143 | 0.470 |
Why?
|
| Neutrophils | 5 | 2022 | 3767 | 0.470 |
Why?
|
| Tumor Microenvironment | 11 | 2024 | 3844 | 0.470 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 4 | 2024 | 317 | 0.470 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2021 | 151 | 0.460 |
Why?
|
| ABO Blood-Group System | 2 | 2015 | 369 | 0.450 |
Why?
|
| Risk Assessment | 43 | 2024 | 24123 | 0.450 |
Why?
|
| Double-Blind Method | 10 | 2024 | 12427 | 0.440 |
Why?
|
| Cohort Studies | 39 | 2023 | 41335 | 0.440 |
Why?
|
| Risk | 14 | 2018 | 9631 | 0.430 |
Why?
|
| Infection Control | 1 | 2020 | 983 | 0.420 |
Why?
|
| High-Throughput Nucleotide Sequencing | 13 | 2021 | 3616 | 0.420 |
Why?
|
| Logistic Models | 23 | 2019 | 13314 | 0.420 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 586 | 0.420 |
Why?
|
| Epigenomics | 5 | 2024 | 936 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2011 | 748 | 0.410 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 698 | 0.410 |
Why?
|
| Prospective Studies | 37 | 2024 | 54303 | 0.400 |
Why?
|
| Uveitis | 1 | 2016 | 393 | 0.400 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 551 | 0.390 |
Why?
|
| Administration, Oral | 9 | 2024 | 4035 | 0.390 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2013 | 267 | 0.390 |
Why?
|
| Renin-Angiotensin System | 2 | 2022 | 738 | 0.390 |
Why?
|
| Nomograms | 3 | 2020 | 238 | 0.390 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2024 | 5251 | 0.390 |
Why?
|
| Intention to Treat Analysis | 3 | 2021 | 422 | 0.380 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2014 | 412 | 0.380 |
Why?
|
| Adenocarcinoma | 9 | 2024 | 6315 | 0.380 |
Why?
|
| Vinca Alkaloids | 1 | 2011 | 36 | 0.380 |
Why?
|
| Hyponatremia | 1 | 2013 | 279 | 0.370 |
Why?
|
| Nuclear Proteins | 6 | 2022 | 5791 | 0.370 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 621 | 0.370 |
Why?
|
| Signal Transduction | 27 | 2022 | 23376 | 0.370 |
Why?
|
| Immunohistochemistry | 16 | 2019 | 11071 | 0.360 |
Why?
|
| DNA-Binding Proteins | 11 | 2022 | 9585 | 0.360 |
Why?
|
| Incidence | 27 | 2023 | 21392 | 0.360 |
Why?
|
| Arthritis | 1 | 2016 | 666 | 0.360 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2017 | 494 | 0.350 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2022 | 2864 | 0.350 |
Why?
|
| Organoplatinum Compounds | 4 | 2017 | 410 | 0.350 |
Why?
|
| Treatment Failure | 9 | 2013 | 2648 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 18 | 2024 | 17790 | 0.340 |
Why?
|
| Transcription Factors | 10 | 2023 | 12103 | 0.340 |
Why?
|
| Hemorrhage | 3 | 2022 | 3600 | 0.340 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 796 | 0.340 |
Why?
|
| Odds Ratio | 18 | 2022 | 9716 | 0.330 |
Why?
|
| Polyethylene Glycols | 5 | 2022 | 1189 | 0.330 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 2717 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 410 | 0.330 |
Why?
|
| Diphosphonates | 1 | 2014 | 638 | 0.320 |
Why?
|
| Endonucleases | 3 | 2017 | 370 | 0.320 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2006 | 96 | 0.320 |
Why?
|
| Brachytherapy | 10 | 2018 | 1238 | 0.320 |
Why?
|
| Biomedical Research | 2 | 2022 | 3426 | 0.310 |
Why?
|
| Venous Thromboembolism | 4 | 2022 | 1864 | 0.310 |
Why?
|
| Predictive Value of Tests | 19 | 2024 | 15289 | 0.310 |
Why?
|
| Metformin | 1 | 2016 | 912 | 0.310 |
Why?
|
| Sarcoma | 1 | 2019 | 1786 | 0.310 |
Why?
|
| Liver Neoplasms | 6 | 2023 | 4319 | 0.310 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 2 | 2022 | 259 | 0.310 |
Why?
|
| Sodium | 1 | 2013 | 1594 | 0.310 |
Why?
|
| Weight Loss | 1 | 2019 | 2686 | 0.300 |
Why?
|
| Marital Status | 5 | 2016 | 433 | 0.300 |
Why?
|
| Hospitals | 8 | 2023 | 3928 | 0.290 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 2250 | 0.290 |
Why?
|
| Prostate | 7 | 2022 | 1793 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 15789 | 0.280 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 496 | 0.280 |
Why?
|
| Insurance, Health | 5 | 2019 | 2501 | 0.280 |
Why?
|
| Interferon-alpha | 3 | 2018 | 918 | 0.280 |
Why?
|
| Watchful Waiting | 4 | 2020 | 510 | 0.280 |
Why?
|
| Drug Delivery Systems | 6 | 2011 | 2221 | 0.270 |
Why?
|
| Analgesics | 1 | 2013 | 1065 | 0.270 |
Why?
|
| Age Factors | 20 | 2020 | 18416 | 0.270 |
Why?
|
| DNA Methylation | 10 | 2024 | 4373 | 0.270 |
Why?
|
| Forecasting | 5 | 2019 | 2932 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2022 | 20509 | 0.270 |
Why?
|
| Acute Kidney Injury | 4 | 2021 | 1941 | 0.260 |
Why?
|
| Cryosurgery | 1 | 2011 | 475 | 0.260 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2018 | 1153 | 0.260 |
Why?
|
| Single-Blind Method | 2 | 2020 | 1578 | 0.260 |
Why?
|
| Interleukin-2 | 4 | 2015 | 1889 | 0.260 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2010 | 752 | 0.260 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2020 | 678 | 0.260 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 2418 | 0.260 |
Why?
|
| Interleukin-7 | 2 | 2022 | 142 | 0.250 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2022 | 4550 | 0.250 |
Why?
|
| Multivariate Analysis | 17 | 2018 | 12159 | 0.250 |
Why?
|
| RNA, Neoplasm | 4 | 2016 | 749 | 0.250 |
Why?
|
| Recurrence | 8 | 2021 | 8482 | 0.250 |
Why?
|
| DNA Copy Number Variations | 10 | 2023 | 2013 | 0.250 |
Why?
|
| Neovascularization, Pathologic | 4 | 2020 | 2640 | 0.250 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 938 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2255 | 0.240 |
Why?
|
| Ureteral Neoplasms | 2 | 2016 | 110 | 0.240 |
Why?
|
| Thalidomide | 2 | 2006 | 884 | 0.240 |
Why?
|
| Platinum Compounds | 3 | 2017 | 95 | 0.230 |
Why?
|
| Paclitaxel | 6 | 2019 | 1736 | 0.230 |
Why?
|
| Kallikreins | 4 | 2018 | 231 | 0.230 |
Why?
|
| Osteoporosis | 1 | 2013 | 1600 | 0.220 |
Why?
|
| Gene Expression | 7 | 2022 | 7588 | 0.220 |
Why?
|
| Cell Line, Tumor | 10 | 2023 | 16939 | 0.220 |
Why?
|
| Hemoglobins | 5 | 2017 | 1521 | 0.220 |
Why?
|
| Rare Diseases | 2 | 2020 | 619 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 2448 | 0.220 |
Why?
|
| Genome-Wide Association Study | 7 | 2024 | 12626 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 2053 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 9 | 2018 | 3618 | 0.220 |
Why?
|
| Telemedicine | 4 | 2021 | 3018 | 0.220 |
Why?
|
| Models, Biological | 5 | 2013 | 9467 | 0.220 |
Why?
|
| Kidney | 10 | 2023 | 7064 | 0.220 |
Why?
|
| Tissue Extracts | 2 | 2017 | 140 | 0.220 |
Why?
|
| Genome, Human | 5 | 2018 | 4417 | 0.220 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 21025 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 1115 | 0.210 |
Why?
|
| Hypothyroidism | 2 | 2018 | 665 | 0.210 |
Why?
|
| Socioeconomic Factors | 11 | 2020 | 7806 | 0.210 |
Why?
|
| ROC Curve | 4 | 2024 | 3568 | 0.210 |
Why?
|
| Postoperative Complications | 6 | 2017 | 15697 | 0.210 |
Why?
|
| Health Services Accessibility | 5 | 2023 | 5397 | 0.210 |
Why?
|
| Quinazolines | 4 | 2014 | 1363 | 0.210 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2024 | 155 | 0.200 |
Why?
|
| Fatigue | 3 | 2019 | 1544 | 0.200 |
Why?
|
| International Cooperation | 5 | 2020 | 1433 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 3334 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 7408 | 0.200 |
Why?
|
| HLA-A3 Antigen | 1 | 2021 | 34 | 0.200 |
Why?
|
| Boston | 3 | 2024 | 9280 | 0.200 |
Why?
|
| Penile Neoplasms | 1 | 2023 | 162 | 0.200 |
Why?
|
| Canada | 4 | 2024 | 2128 | 0.200 |
Why?
|
| Ischemia | 1 | 2010 | 1893 | 0.200 |
Why?
|
| Phthalazines | 1 | 2024 | 383 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 4 | 2021 | 2180 | 0.200 |
Why?
|
| Up-Regulation | 3 | 2022 | 4122 | 0.190 |
Why?
|
| Adjuvants, Immunologic | 2 | 2024 | 1039 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2020 | 326 | 0.190 |
Why?
|
| Insurance Coverage | 4 | 2019 | 1939 | 0.190 |
Why?
|
| Adenoma | 1 | 2012 | 2148 | 0.190 |
Why?
|
| Amylases | 2 | 2019 | 169 | 0.190 |
Why?
|
| Butylamines | 1 | 2021 | 9 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.190 |
Why?
|
| Genealogy and Heraldry | 1 | 2021 | 29 | 0.190 |
Why?
|
| Lymphocyte Count | 3 | 2024 | 780 | 0.190 |
Why?
|
| Medically Uninsured | 3 | 2016 | 843 | 0.190 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2021 | 83 | 0.190 |
Why?
|
| Myocarditis | 2 | 2019 | 766 | 0.190 |
Why?
|
| Benzoxazoles | 1 | 2022 | 89 | 0.190 |
Why?
|
| Erythropoietin | 2 | 2021 | 720 | 0.190 |
Why?
|
| Diarrhea | 2 | 2019 | 1319 | 0.180 |
Why?
|
| Immune System Diseases | 1 | 2023 | 258 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2017 | 1791 | 0.180 |
Why?
|
| Models, Statistical | 1 | 2015 | 5075 | 0.180 |
Why?
|
| Receptors, Androgen | 3 | 2022 | 1077 | 0.180 |
Why?
|
| Aminoquinolines | 1 | 2021 | 108 | 0.180 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 1303 | 0.180 |
Why?
|
| Minority Health | 2 | 2019 | 81 | 0.180 |
Why?
|
| Health Expenditures | 3 | 2020 | 2362 | 0.180 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2002 | 141 | 0.180 |
Why?
|
| Guidelines as Topic | 3 | 2015 | 1392 | 0.180 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 33 | 0.180 |
Why?
|
| Lymphatic Metastasis | 7 | 2017 | 2943 | 0.180 |
Why?
|
| Aromatase Inhibitors | 1 | 2004 | 511 | 0.180 |
Why?
|
| Cause of Death | 10 | 2022 | 3725 | 0.180 |
Why?
|
| Telomerase | 2 | 2024 | 746 | 0.180 |
Why?
|
| Pneumonia | 1 | 2012 | 2131 | 0.180 |
Why?
|
| Heart Failure | 4 | 2014 | 11847 | 0.180 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 4107 | 0.180 |
Why?
|
| Georgia | 1 | 2020 | 190 | 0.170 |
Why?
|
| Hypertension | 6 | 2022 | 8594 | 0.170 |
Why?
|
| Cell Respiration | 1 | 2020 | 202 | 0.170 |
Why?
|
| Comparative Effectiveness Research | 3 | 2020 | 718 | 0.170 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2021 | 150 | 0.170 |
Why?
|
| Radiography | 3 | 2016 | 6965 | 0.170 |
Why?
|
| Camptothecin | 1 | 2023 | 590 | 0.170 |
Why?
|
| Phenotype | 11 | 2023 | 16546 | 0.170 |
Why?
|
| Thyroid Neoplasms | 2 | 2024 | 2332 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 5 | 2021 | 877 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 161 | 0.170 |
Why?
|
| Cancer Care Facilities | 3 | 2017 | 424 | 0.170 |
Why?
|
| Databases, Genetic | 3 | 2021 | 1738 | 0.160 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2019 | 128 | 0.160 |
Why?
|
| Lipase | 2 | 2019 | 324 | 0.160 |
Why?
|
| Penetrance | 1 | 2021 | 388 | 0.160 |
Why?
|
| Genes, Neoplasm | 1 | 2021 | 370 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 2 | 2024 | 2882 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 373 | 0.160 |
Why?
|
| Therapeutics | 1 | 2019 | 114 | 0.160 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 5799 | 0.160 |
Why?
|
| Regression Analysis | 7 | 2017 | 6360 | 0.160 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2020 | 102 | 0.160 |
Why?
|
| Alanine Transaminase | 2 | 2019 | 606 | 0.160 |
Why?
|
| Viruses | 1 | 2022 | 376 | 0.160 |
Why?
|
| Spain | 1 | 2020 | 488 | 0.160 |
Why?
|
| Drugs, Investigational | 1 | 2021 | 214 | 0.160 |
Why?
|
| Biology | 1 | 2021 | 290 | 0.160 |
Why?
|
| Income | 4 | 2014 | 1875 | 0.160 |
Why?
|
| Tyrosine | 1 | 2023 | 1438 | 0.160 |
Why?
|
| Adolescent | 16 | 2024 | 87810 | 0.160 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2002 | 241 | 0.160 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 491 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 4 | 2020 | 2005 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 534 | 0.150 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 895 | 0.150 |
Why?
|
| Quantitative Trait Loci | 2 | 2024 | 2101 | 0.150 |
Why?
|
| Observer Variation | 3 | 2015 | 2601 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2023 | 2506 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2018 | 105 | 0.150 |
Why?
|
| Divorce | 1 | 2018 | 76 | 0.150 |
Why?
|
| Drug Repositioning | 1 | 2020 | 232 | 0.150 |
Why?
|
| Hospital Costs | 2 | 2016 | 976 | 0.150 |
Why?
|
| Receptor, erbB-2 | 5 | 2016 | 2554 | 0.150 |
Why?
|
| Glutathione Peroxidase | 1 | 2019 | 256 | 0.150 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 139 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 346 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2011 | 2758 | 0.150 |
Why?
|
| Chromosome Deletion | 2 | 2020 | 1387 | 0.150 |
Why?
|
| Gene Dosage | 4 | 2015 | 1218 | 0.150 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2017 | 53 | 0.150 |
Why?
|
| Medicare | 6 | 2019 | 6786 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.150 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 118 | 0.150 |
Why?
|
| Platinum | 2 | 2015 | 223 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 3527 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 3164 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2024 | 1596 | 0.140 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 489 | 0.140 |
Why?
|
| Histone Demethylases | 1 | 2020 | 323 | 0.140 |
Why?
|
| Travel | 1 | 2023 | 785 | 0.140 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 199 | 0.140 |
Why?
|
| Robotics | 3 | 2014 | 874 | 0.140 |
Why?
|
| Multiple Myeloma | 4 | 2007 | 5130 | 0.140 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 38 | 0.140 |
Why?
|
| Cadherins | 1 | 2021 | 898 | 0.140 |
Why?
|
| Animals | 23 | 2024 | 167963 | 0.140 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 638 | 0.140 |
Why?
|
| Warfarin | 2 | 2022 | 1518 | 0.140 |
Why?
|
| Gene Deletion | 3 | 2020 | 2668 | 0.140 |
Why?
|
| Radioisotopes | 1 | 2018 | 495 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2022 | 558 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2018 | 356 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 5 | 2021 | 4713 | 0.140 |
Why?
|
| Cost of Illness | 3 | 2015 | 1940 | 0.140 |
Why?
|
| Smoking | 3 | 2024 | 9073 | 0.140 |
Why?
|
| Thrombosis | 1 | 2010 | 3052 | 0.130 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2016 | 37 | 0.130 |
Why?
|
| Seminoma | 2 | 2015 | 134 | 0.130 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 65 | 0.130 |
Why?
|
| Venous Thrombosis | 2 | 2003 | 1299 | 0.130 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 10181 | 0.130 |
Why?
|
| Muscle Neoplasms | 1 | 2017 | 133 | 0.130 |
Why?
|
| Chemokine CXCL9 | 1 | 2016 | 135 | 0.130 |
Why?
|
| Retreatment | 4 | 2021 | 600 | 0.130 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 786 | 0.130 |
Why?
|
| Synovitis | 1 | 2017 | 215 | 0.130 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 728 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2018 | 2913 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2020 | 2471 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 1446 | 0.130 |
Why?
|
| Publication Bias | 2 | 2014 | 162 | 0.130 |
Why?
|
| Biopsy | 6 | 2019 | 6771 | 0.130 |
Why?
|
| Health Status | 3 | 2022 | 4081 | 0.130 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 71 | 0.130 |
Why?
|
| Complementarity Determining Regions | 1 | 2016 | 149 | 0.130 |
Why?
|
| Colorectal Neoplasms | 7 | 2021 | 6853 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2021 | 858 | 0.130 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 97 | 0.130 |
Why?
|
| Vaccines, Subunit | 1 | 2016 | 161 | 0.130 |
Why?
|
| Multigene Family | 1 | 2018 | 1077 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 981 | 0.130 |
Why?
|
| Protein Kinases | 2 | 2015 | 1612 | 0.130 |
Why?
|
| Obesity | 3 | 2022 | 12922 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 650 | 0.130 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 2754 | 0.130 |
Why?
|
| Health Status Disparities | 3 | 2023 | 1830 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 995 | 0.120 |
Why?
|
| Epidemiologic Studies | 2 | 2021 | 670 | 0.120 |
Why?
|
| Chi-Square Distribution | 5 | 2018 | 3465 | 0.120 |
Why?
|
| Research | 1 | 2024 | 1974 | 0.120 |
Why?
|
| Air Pollution, Indoor | 1 | 2022 | 893 | 0.120 |
Why?
|
| Disease Management | 5 | 2020 | 2514 | 0.120 |
Why?
|
| Proteinuria | 1 | 2018 | 594 | 0.120 |
Why?
|
| Body Mass Index | 6 | 2022 | 12914 | 0.120 |
Why?
|
| Creatinine | 2 | 2020 | 1903 | 0.120 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 316 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 3726 | 0.120 |
Why?
|
| Health Care Costs | 3 | 2020 | 3258 | 0.120 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2014 | 43 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2018 | 547 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2020 | 854 | 0.120 |
Why?
|
| Piperidines | 2 | 2014 | 1650 | 0.120 |
Why?
|
| Piperazines | 2 | 2024 | 2525 | 0.120 |
Why?
|
| Interferon-gamma | 3 | 2020 | 3157 | 0.120 |
Why?
|
| Antigen Presentation | 1 | 2020 | 1254 | 0.120 |
Why?
|
| Mucositis | 1 | 2015 | 108 | 0.120 |
Why?
|
| Comorbidity | 7 | 2021 | 10551 | 0.120 |
Why?
|
| Accidents | 1 | 2015 | 166 | 0.120 |
Why?
|
| Bone Remodeling | 1 | 2018 | 580 | 0.120 |
Why?
|
| Placebos | 3 | 2017 | 1668 | 0.120 |
Why?
|
| Confidence Intervals | 3 | 2015 | 2932 | 0.120 |
Why?
|
| Filgrastim | 1 | 2014 | 132 | 0.120 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2014 | 106 | 0.120 |
Why?
|
| Heart Neoplasms | 1 | 2017 | 360 | 0.120 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 795 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2020 | 1195 | 0.120 |
Why?
|
| Drug Approval | 1 | 2021 | 816 | 0.110 |
Why?
|
| Doxorubicin | 2 | 2014 | 2209 | 0.110 |
Why?
|
| Insurance Benefits | 1 | 2016 | 191 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2018 | 6538 | 0.110 |
Why?
|
| Drug Therapy | 2 | 2014 | 504 | 0.110 |
Why?
|
| Quality of Health Care | 3 | 2019 | 4360 | 0.110 |
Why?
|
| Video Recording | 1 | 2019 | 955 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 1705 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2020 | 1313 | 0.110 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 23 | 0.110 |
Why?
|
| Suicide | 2 | 2015 | 1599 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2018 | 570 | 0.110 |
Why?
|
| Urban Population | 1 | 2022 | 2022 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 74 | 0.110 |
Why?
|
| Perioperative Care | 2 | 2019 | 1037 | 0.110 |
Why?
|
| Germ Cells | 3 | 2022 | 635 | 0.110 |
Why?
|
| Geriatrics | 1 | 2018 | 387 | 0.110 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 752 | 0.110 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 15757 | 0.110 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 72 | 0.110 |
Why?
|
| Apoptosis | 3 | 2019 | 9501 | 0.110 |
Why?
|
| Radiotherapy | 4 | 2017 | 1504 | 0.110 |
Why?
|
| Muscles | 1 | 2018 | 1581 | 0.110 |
Why?
|
| Drug Therapy, Combination | 5 | 2020 | 6498 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1440 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 130 | 0.110 |
Why?
|
| Liver Function Tests | 1 | 2014 | 524 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 789 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 2017 | 924 | 0.110 |
Why?
|
| Morpholines | 1 | 2016 | 583 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 126 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 376 | 0.110 |
Why?
|
| Epigenesis, Genetic | 4 | 2024 | 3758 | 0.100 |
Why?
|
| Propensity Score | 5 | 2019 | 1928 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2018 | 1187 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2015 | 597 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2021 | 1131 | 0.100 |
Why?
|
| Hypocalcemia | 1 | 2014 | 199 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2017 | 1428 | 0.100 |
Why?
|
| Heme Oxygenase-1 | 1 | 2015 | 364 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2013 | 172 | 0.100 |
Why?
|
| Aminopyridines | 1 | 2016 | 564 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2015 | 674 | 0.100 |
Why?
|
| MicroRNAs | 4 | 2016 | 3790 | 0.100 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 705 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 230 | 0.100 |
Why?
|
| Lymph Nodes | 4 | 2017 | 3486 | 0.100 |
Why?
|
| Vaccination | 2 | 2021 | 3361 | 0.100 |
Why?
|
| Urology | 1 | 2017 | 423 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 7475 | 0.100 |
Why?
|
| Epidemiologic Methods | 3 | 2015 | 1343 | 0.100 |
Why?
|
| Alleles | 4 | 2021 | 6898 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2016 | 1600 | 0.100 |
Why?
|
| Penis | 1 | 2013 | 212 | 0.100 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 778 | 0.100 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1745 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 1423 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2022 | 1999 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 796 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 1628 | 0.090 |
Why?
|
| Community Health Services | 1 | 2016 | 654 | 0.090 |
Why?
|
| Rural Population | 1 | 2022 | 2268 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2021 | 4000 | 0.090 |
Why?
|
| Telomere | 1 | 2017 | 933 | 0.090 |
Why?
|
| Genotype | 3 | 2015 | 12960 | 0.090 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2016 | 208 | 0.090 |
Why?
|
| Treatment Refusal | 1 | 2014 | 430 | 0.090 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 1405 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2299 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 3839 | 0.090 |
Why?
|
| Minority Groups | 1 | 2018 | 1201 | 0.090 |
Why?
|
| Postoperative Period | 2 | 2018 | 1818 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 1031 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 508 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 2696 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2018 | 2003 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1895 | 0.090 |
Why?
|
| Metabolomics | 1 | 2019 | 1628 | 0.090 |
Why?
|
| Mass Screening | 3 | 2021 | 5423 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2021 | 2869 | 0.090 |
Why?
|
| Sex Factors | 7 | 2020 | 10547 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2022 | 4897 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 600 | 0.080 |
Why?
|
| Enteritis | 1 | 2011 | 162 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2016 | 965 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 4166 | 0.080 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 557 | 0.080 |
Why?
|
| Cancer Vaccines | 3 | 2016 | 1046 | 0.080 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 1516 | 0.080 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 20080 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 675 | 0.080 |
Why?
|
| Arteries | 2 | 2012 | 1126 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 225 | 0.080 |
Why?
|
| Neutropenia | 2 | 2012 | 884 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2013 | 2234 | 0.080 |
Why?
|
| Heart Conduction System | 1 | 2014 | 1015 | 0.080 |
Why?
|
| Remission Induction | 1 | 2015 | 2392 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3696 | 0.080 |
Why?
|
| Oxygen | 1 | 2020 | 4193 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 633 | 0.080 |
Why?
|
| Anemia, Macrocytic | 1 | 2008 | 54 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 1190 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2018 | 3442 | 0.080 |
Why?
|
| Prednisone | 2 | 2023 | 1565 | 0.080 |
Why?
|
| Methionine | 1 | 2010 | 569 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2015 | 2283 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 4024 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1810 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 820 | 0.070 |
Why?
|
| Cardiology | 1 | 2019 | 1723 | 0.070 |
Why?
|
| Nitriles | 2 | 2021 | 956 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2015 | 36290 | 0.070 |
Why?
|
| Hospice Care | 1 | 2015 | 692 | 0.070 |
Why?
|
| Karyotyping | 1 | 2009 | 1171 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2014 | 1100 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 186 | 0.070 |
Why?
|
| Macrophages | 3 | 2021 | 5745 | 0.070 |
Why?
|
| Methotrexate | 1 | 2014 | 1719 | 0.070 |
Why?
|
| Acetaminophen | 1 | 2011 | 553 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 1246 | 0.070 |
Why?
|
| Patient Admission | 1 | 2015 | 1386 | 0.070 |
Why?
|
| Paxillin | 1 | 2007 | 86 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2557 | 0.070 |
Why?
|
| Demography | 3 | 2018 | 1650 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2011 | 682 | 0.070 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2012 | 1008 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2008 | 112 | 0.070 |
Why?
|
| Laparoscopy | 3 | 2019 | 2147 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7593 | 0.070 |
Why?
|
| Genetic Variation | 3 | 2022 | 6551 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5425 | 0.070 |
Why?
|
| Proteomics | 2 | 2017 | 3817 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 2007 | 222 | 0.070 |
Why?
|
| Child | 6 | 2021 | 79806 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2021 | 8313 | 0.070 |
Why?
|
| RNA, Messenger | 6 | 2016 | 12766 | 0.070 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2006 | 46 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5201 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2022 | 3598 | 0.070 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 427 | 0.070 |
Why?
|
| Urethra | 1 | 2008 | 406 | 0.070 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2006 | 60 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 412 | 0.070 |
Why?
|
| Diffusion of Innovation | 1 | 2011 | 730 | 0.070 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 11891 | 0.070 |
Why?
|
| Endothelins | 1 | 2006 | 127 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 1347 | 0.060 |
Why?
|
| Caveolin 1 | 1 | 2007 | 257 | 0.060 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 25942 | 0.060 |
Why?
|
| Karnofsky Performance Status | 2 | 2017 | 165 | 0.060 |
Why?
|
| Chromatin | 2 | 2016 | 2938 | 0.060 |
Why?
|
| Biological Products | 1 | 2014 | 916 | 0.060 |
Why?
|
| Radiology | 1 | 2019 | 2102 | 0.060 |
Why?
|
| Daptomycin | 1 | 2005 | 71 | 0.060 |
Why?
|
| Dementia | 1 | 2019 | 2649 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2020 | 4264 | 0.060 |
Why?
|
| Chorionic Gonadotropin | 1 | 2007 | 457 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 358 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 497 | 0.060 |
Why?
|
| Interferons | 1 | 2008 | 705 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 2001 | 0.060 |
Why?
|
| Enterococcus faecium | 1 | 2005 | 101 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2013 | 2440 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 1894 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2061 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1380 | 0.060 |
Why?
|
| Carboplatin | 2 | 2020 | 788 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 14495 | 0.060 |
Why?
|
| Activated Protein C Resistance | 1 | 2003 | 18 | 0.060 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 844 | 0.060 |
Why?
|
| Eligibility Determination | 2 | 2021 | 421 | 0.060 |
Why?
|
| Case-Control Studies | 6 | 2024 | 22053 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2006 | 340 | 0.060 |
Why?
|
| Medical Records | 1 | 2009 | 1407 | 0.060 |
Why?
|
| Random Allocation | 2 | 2019 | 2394 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1722 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 6068 | 0.060 |
Why?
|
| DNA Primers | 1 | 2008 | 2819 | 0.060 |
Why?
|
| Sphingosine | 1 | 2006 | 308 | 0.060 |
Why?
|
| Weight Gain | 1 | 2014 | 2347 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 2634 | 0.060 |
Why?
|
| Lysophospholipids | 1 | 2006 | 339 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2018 | 724 | 0.060 |
Why?
|
| INDEL Mutation | 2 | 2015 | 266 | 0.050 |
Why?
|
| Levivirus | 1 | 2023 | 14 | 0.050 |
Why?
|
| Castration | 1 | 2023 | 153 | 0.050 |
Why?
|
| Terminal Care | 1 | 2015 | 1758 | 0.050 |
Why?
|
| Testosterone | 1 | 2014 | 2470 | 0.050 |
Why?
|
| Factor V | 1 | 2003 | 168 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 1174 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2013 | 1915 | 0.050 |
Why?
|
| Survival | 2 | 2013 | 161 | 0.050 |
Why?
|
| Oximes | 1 | 2024 | 306 | 0.050 |
Why?
|
| Caspases | 1 | 2006 | 878 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2013 | 2560 | 0.050 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2005 | 343 | 0.050 |
Why?
|
| Overweight | 1 | 2014 | 2421 | 0.050 |
Why?
|
| Prevalence | 4 | 2021 | 15687 | 0.050 |
Why?
|
| Androstadienes | 1 | 2004 | 348 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 3084 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5325 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 998 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 177 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 5351 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 3763 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2005 | 695 | 0.050 |
Why?
|
| Drug Costs | 1 | 2010 | 1185 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 12965 | 0.050 |
Why?
|
| Lymphopenia | 1 | 2024 | 280 | 0.050 |
Why?
|
| Tennessee | 1 | 2021 | 119 | 0.050 |
Why?
|
| Free Radicals | 1 | 2002 | 238 | 0.050 |
Why?
|
| Aging | 2 | 2018 | 8651 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2010 | 2141 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2023 | 3106 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3726 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2024 | 586 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 2006 | 2210 | 0.050 |
Why?
|
| Nutrition Disorders | 1 | 2022 | 205 | 0.050 |
Why?
|
| London | 1 | 2021 | 234 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1630 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 1135 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2021 | 56 | 0.050 |
Why?
|
| Urinary Bladder | 2 | 2017 | 1166 | 0.050 |
Why?
|
| Paraproteinemias | 1 | 2003 | 246 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 42063 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2011 | 2912 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2017 | 4647 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 201 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2022 | 345 | 0.050 |
Why?
|
| Liver | 2 | 2013 | 7509 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2019 | 3607 | 0.040 |
Why?
|
| Morbidity | 2 | 2017 | 1765 | 0.040 |
Why?
|
| ras Proteins | 2 | 2016 | 1052 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 15840 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2002 | 386 | 0.040 |
Why?
|
| Inpatients | 1 | 2012 | 2581 | 0.040 |
Why?
|
| Vincristine | 1 | 2002 | 1039 | 0.040 |
Why?
|
| Japan | 2 | 2015 | 1369 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 3448 | 0.040 |
Why?
|
| Length of Stay | 4 | 2017 | 6479 | 0.040 |
Why?
|
| Probability | 2 | 2020 | 2475 | 0.040 |
Why?
|
| Pelvis | 2 | 2017 | 743 | 0.040 |
Why?
|
| Self Report | 3 | 2016 | 3711 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 165 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2014 | 5990 | 0.040 |
Why?
|
| Androstenes | 1 | 2021 | 182 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2024 | 613 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2021 | 204 | 0.040 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 421 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 551 | 0.040 |
Why?
|
| Age of Onset | 3 | 2015 | 3301 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 693 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 224 | 0.040 |
Why?
|
| Anxiety | 1 | 2014 | 4538 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2002 | 306 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 1096 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2021 | 524 | 0.040 |
Why?
|
| History, 21st Century | 2 | 2015 | 1575 | 0.040 |
Why?
|
| Benzamides | 2 | 2021 | 1369 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2003 | 709 | 0.040 |
Why?
|
| Massachusetts | 3 | 2021 | 8803 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 361 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 468 | 0.040 |
Why?
|
| Kynurenine | 1 | 2019 | 139 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 354 | 0.040 |
Why?
|
| Granzymes | 1 | 2020 | 276 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 200 | 0.040 |
Why?
|
| Triazoles | 1 | 2004 | 904 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7850 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2021 | 358 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 681 | 0.040 |
Why?
|
| Th1-Th2 Balance | 1 | 2018 | 38 | 0.040 |
Why?
|
| Furans | 1 | 2019 | 199 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2698 | 0.040 |
Why?
|
| Paresthesia | 1 | 2019 | 162 | 0.040 |
Why?
|
| Hospitalization | 2 | 2015 | 10790 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2024 | 5785 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 2471 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2019 | 271 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 283 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 1055 | 0.040 |
Why?
|
| Haplotypes | 1 | 2024 | 2764 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 849 | 0.040 |
Why?
|
| Mammography | 2 | 2021 | 2427 | 0.040 |
Why?
|
| Public Health | 2 | 2021 | 2653 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 606 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 479 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2015 | 2773 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2017 | 92 | 0.040 |
Why?
|
| Models, Economic | 2 | 2012 | 719 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 289 | 0.040 |
Why?
|
| Anemia | 1 | 2006 | 1511 | 0.040 |
Why?
|
| Oncogenes | 1 | 2023 | 1220 | 0.040 |
Why?
|
| Troponin T | 1 | 2022 | 774 | 0.030 |
Why?
|
| Patient Care Team | 2 | 2022 | 2511 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 2221 | 0.030 |
Why?
|
| Plasma | 1 | 2020 | 584 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2014 | 2295 | 0.030 |
Why?
|
| Health Facilities | 1 | 2022 | 578 | 0.030 |
Why?
|
| HIV Infections | 1 | 2023 | 17165 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 788 | 0.030 |
Why?
|
| Organ Size | 2 | 2013 | 2254 | 0.030 |
Why?
|
| Educational Status | 2 | 2014 | 2515 | 0.030 |
Why?
|
| Cricetulus | 1 | 2018 | 815 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 8044 | 0.030 |
Why?
|
| Social Class | 2 | 2016 | 2005 | 0.030 |
Why?
|
| Marriage | 1 | 2018 | 350 | 0.030 |
Why?
|
| Korea | 1 | 2015 | 96 | 0.030 |
Why?
|
| Computational Biology | 2 | 2019 | 3505 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2017 | 161 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2021 | 1091 | 0.030 |
Why?
|
| Philippines | 1 | 2015 | 91 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2024 | 11481 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 802 | 0.030 |
Why?
|
| Antibodies | 1 | 2024 | 2421 | 0.030 |
Why?
|
| DNA Repair | 2 | 2015 | 2039 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2873 | 0.030 |
Why?
|
| Mortality | 2 | 2019 | 2916 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 296 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2023 | 1612 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2326 | 0.030 |
Why?
|
| CHO Cells | 1 | 2018 | 1389 | 0.030 |
Why?
|
| Cost Sharing | 1 | 2019 | 410 | 0.030 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2015 | 122 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2015 | 133 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1523 | 0.030 |
Why?
|
| Fumarate Hydratase | 1 | 2015 | 52 | 0.030 |
Why?
|
| Epidemics | 1 | 2021 | 510 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 188 | 0.030 |
Why?
|
| Vietnam | 1 | 2015 | 411 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2015 | 159 | 0.030 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2015 | 163 | 0.030 |
Why?
|
| Heparin | 1 | 2002 | 1652 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8950 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 2828 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 93 | 0.030 |
Why?
|
| Syndrome | 1 | 2021 | 3280 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2015 | 397 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2017 | 458 | 0.030 |
Why?
|
| Acute Disease | 2 | 2021 | 7269 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1660 | 0.030 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2015 | 123 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2022 | 850 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 245 | 0.030 |
Why?
|
| Cell Line | 2 | 2020 | 15620 | 0.030 |
Why?
|
| Goserelin | 1 | 2014 | 127 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2017 | 371 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2014 | 173 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 6465 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2014 | 1200 | 0.030 |
Why?
|
| Gilbert Disease | 1 | 2013 | 4 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 1411 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2024 | 2629 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 464 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2014 | 5434 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2016 | 296 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2020 | 2362 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1724 | 0.030 |
Why?
|
| Pedigree | 1 | 2021 | 4578 | 0.030 |
Why?
|
| Brazil | 1 | 2017 | 1218 | 0.030 |
Why?
|
| Cost Savings | 1 | 2019 | 920 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 301 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2017 | 453 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2014 | 6238 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 620 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 1077 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1385 | 0.030 |
Why?
|
| Cardiotoxins | 1 | 2013 | 37 | 0.030 |
Why?
|
| Genome | 1 | 2021 | 1739 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 3765 | 0.030 |
Why?
|
| Diaphragm | 1 | 2014 | 351 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 473 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 727 | 0.030 |
Why?
|
| Natural Language Processing | 1 | 2021 | 1135 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2021 | 1387 | 0.030 |
Why?
|
| Leuprolide | 1 | 2014 | 315 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 786 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 162 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1677 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 1296 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2017 | 1085 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 727 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 801 | 0.030 |
Why?
|
| Singapore | 1 | 2013 | 288 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2019 | 2608 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 442 | 0.030 |
Why?
|
| Patient Readmission | 2 | 2017 | 3323 | 0.030 |
Why?
|
| Immunity | 1 | 2018 | 998 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2019 | 2435 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1791 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2019 | 1248 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 1122 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2015 | 829 | 0.020 |
Why?
|
| Tumor Escape | 1 | 2015 | 370 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 2536 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 132 | 0.020 |
Why?
|
| Bilirubin | 1 | 2013 | 438 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 635 | 0.020 |
Why?
|
| Homozygote | 1 | 2016 | 1788 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2015 | 788 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 1416 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2023 | 3047 | 0.020 |
Why?
|
| Republic of Korea | 1 | 2013 | 566 | 0.020 |
Why?
|
| Office Visits | 1 | 2015 | 597 | 0.020 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2010 | 80 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2019 | 8525 | 0.020 |
Why?
|
| CpG Islands | 1 | 2015 | 1221 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2014 | 1167 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2015 | 1342 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 798 | 0.020 |
Why?
|
| Denmark | 1 | 2013 | 760 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2020 | 2145 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3584 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2016 | 1368 | 0.020 |
Why?
|
| Internationality | 1 | 2016 | 1004 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2622 | 0.020 |
Why?
|
| Iron | 1 | 2019 | 1786 | 0.020 |
Why?
|
| Mice | 3 | 2024 | 81208 | 0.020 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2010 | 56 | 0.020 |
Why?
|
| RNA Interference | 1 | 2019 | 2846 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 1959 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 3075 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 1173 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 749 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2014 | 601 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 1975 | 0.020 |
Why?
|
| Health Occupations | 1 | 2011 | 222 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 2897 | 0.020 |
Why?
|
| China | 1 | 2015 | 2339 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2010 | 395 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2009 | 50 | 0.020 |
Why?
|
| Leukocytes | 1 | 2017 | 2026 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 1147 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 858 | 0.020 |
Why?
|
| Protein Transport | 1 | 2015 | 1964 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 3880 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 5508 | 0.020 |
Why?
|
| Health Surveys | 1 | 2018 | 4063 | 0.020 |
Why?
|
| Research Design | 2 | 2014 | 6180 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2022 | 3736 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5125 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2919 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 507 | 0.020 |
Why?
|
| Norway | 1 | 2009 | 496 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2019 | 1717 | 0.020 |
Why?
|
| Europe | 1 | 2015 | 3441 | 0.020 |
Why?
|
| Military Personnel | 1 | 2017 | 1244 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2008 | 145 | 0.020 |
Why?
|
| Alberta | 1 | 2007 | 66 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1764 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2018 | 2688 | 0.020 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2008 | 85 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2017 | 2618 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2010 | 598 | 0.020 |
Why?
|
| Quebec | 1 | 2007 | 142 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3061 | 0.020 |
Why?
|
| Lipids | 1 | 2019 | 3336 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 1832 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2008 | 238 | 0.020 |
Why?
|
| Stroke | 1 | 2010 | 9962 | 0.020 |
Why?
|
| Decision Making | 1 | 2021 | 3925 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2015 | 1004 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 474 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1728 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2012 | 656 | 0.020 |
Why?
|
| Poland | 1 | 2007 | 196 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2020 | 3531 | 0.020 |
Why?
|
| Health Personnel | 1 | 2021 | 3310 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 1677 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 6131 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 1166 | 0.020 |
Why?
|
| Hormones | 1 | 2011 | 867 | 0.020 |
Why?
|
| Ohio | 1 | 2007 | 333 | 0.020 |
Why?
|
| Wound Healing | 1 | 2018 | 2788 | 0.020 |
Why?
|
| Internet | 1 | 2019 | 3078 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 3735 | 0.020 |
Why?
|
| Albuminuria | 1 | 2010 | 659 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 162 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1456 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 3969 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2021 | 9287 | 0.020 |
Why?
|
| Receptor, Endothelin A | 1 | 2006 | 56 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1399 | 0.020 |
Why?
|
| Receptors, Endothelin | 1 | 2006 | 56 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 1195 | 0.020 |
Why?
|
| Sweden | 1 | 2009 | 1381 | 0.020 |
Why?
|
| DNA | 1 | 2020 | 7233 | 0.020 |
Why?
|
| France | 1 | 2007 | 511 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 1628 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7343 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2007 | 148 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 6216 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2007 | 217 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 551 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 1824 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2015 | 3682 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2013 | 895 | 0.020 |
Why?
|
| Exercise | 1 | 2002 | 5787 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 1428 | 0.020 |
Why?
|
| Cognition | 1 | 2022 | 6957 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2566 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5797 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 801 | 0.010 |
Why?
|
| RNA | 1 | 2014 | 2722 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2006 | 302 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2019 | 6381 | 0.010 |
Why?
|
| Insulin | 1 | 2019 | 6597 | 0.010 |
Why?
|
| Cartilage | 1 | 2007 | 806 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2014 | 2608 | 0.010 |
Why?
|
| Social Support | 1 | 2013 | 2145 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2893 | 0.010 |
Why?
|
| Base Sequence | 1 | 2014 | 12446 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4611 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2016 | 6218 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 1900 | 0.010 |
Why?
|
| Critical Care | 1 | 2015 | 2699 | 0.010 |
Why?
|
| Cell Movement | 1 | 2014 | 5206 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2014 | 3562 | 0.010 |
Why?
|
| Androgens | 1 | 2010 | 1291 | 0.010 |
Why?
|
| Poverty | 1 | 2014 | 2695 | 0.010 |
Why?
|
| Myoglobin | 1 | 2002 | 159 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2006 | 1130 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 17624 | 0.010 |
Why?
|
| Veterans | 1 | 2015 | 2642 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2011 | 1801 | 0.010 |
Why?
|
| Mitochondria, Muscle | 1 | 2002 | 172 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 1403 | 0.010 |
Why?
|
| Rhabdomyolysis | 1 | 2002 | 155 | 0.010 |
Why?
|
| Emotions | 1 | 2013 | 2734 | 0.010 |
Why?
|
| Tretinoin | 1 | 2003 | 519 | 0.010 |
Why?
|
| Reoperation | 1 | 2010 | 4291 | 0.010 |
Why?
|
| Mental Health | 1 | 2014 | 3213 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 13981 | 0.010 |
Why?
|
| Physical Exertion | 1 | 2002 | 662 | 0.010 |
Why?
|
| Linear Models | 1 | 2008 | 5877 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 1721 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 11903 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2002 | 1201 | 0.010 |
Why?
|
| Heterozygote | 1 | 2003 | 2798 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 9994 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 12293 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2002 | 4925 | 0.000 |
Why?
|